Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition

and the FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition, Zev H. Davidovics, Sonia Michail, Maribeth R. Nicholson, Larry K. Kociolek, Nikhil Pai, Richard Hansen, Tobias Schwerd, Aldo Maspons, Raanan Shamir, Hania Szajewska, Nikhil Thapar, Tim de Meij, Alexis Mosca, Yvan Vandenplas, Stacy A. Kahn, Richard Kellermayer

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.
LanguageEnglish
Pages130-143
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume68
Issue number1
DOIs
Publication statusPublished - 2019

Cite this

@article{c4ba69939e7144f3b919b89aa752e4db,
title = "Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition",
abstract = "Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.",
author = "{and the FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition} and Davidovics, {Zev H.} and Sonia Michail and Nicholson, {Maribeth R.} and Kociolek, {Larry K.} and Nikhil Pai and Richard Hansen and Tobias Schwerd and Aldo Maspons and Raanan Shamir and Hania Szajewska and Nikhil Thapar and {de Meij}, Tim and Alexis Mosca and Yvan Vandenplas and Kahn, {Stacy A.} and Richard Kellermayer",
year = "2019",
doi = "10.1097/MPG.0000000000002205",
language = "English",
volume = "68",
pages = "130--143",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. / and the FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 68, No. 1, 2019, p. 130-143.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition

AU - and the FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition

AU - Davidovics, Zev H.

AU - Michail, Sonia

AU - Nicholson, Maribeth R.

AU - Kociolek, Larry K.

AU - Pai, Nikhil

AU - Hansen, Richard

AU - Schwerd, Tobias

AU - Maspons, Aldo

AU - Shamir, Raanan

AU - Szajewska, Hania

AU - Thapar, Nikhil

AU - de Meij, Tim

AU - Mosca, Alexis

AU - Vandenplas, Yvan

AU - Kahn, Stacy A.

AU - Kellermayer, Richard

PY - 2019

Y1 - 2019

N2 - Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.

AB - Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85059225507&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30540704

U2 - 10.1097/MPG.0000000000002205

DO - 10.1097/MPG.0000000000002205

M3 - Article

VL - 68

SP - 130

EP - 143

JO - Journal of Pediatric Gastroenterology and Nutrition

T2 - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -